Rogier Eric, Plucinski Mateusz, Lucchi Naomi, Mace Kimberly, Chang Michelle, Lemoine Jean Frantz, Candrinho Baltazar, Colborn James, Dimbu Rafael, Fortes Filomeno, Udhayakumar Venkatachalam, Barnwell John
The Centers for Disease Control and Prevention, Center for Global Health, Division of Parasitic Diseases and Malaria, Malaria Branch, Atlanta, GA, United States of America.
Programme National de Contrôle de la Malaria, Ministère de la Santé Publique et de la Population (MSPP), Port-au-Prince, Haiti.
PLoS One. 2017 Feb 13;12(2):e0172139. doi: 10.1371/journal.pone.0172139. eCollection 2017.
Detection of histidine-rich protein 2 (HRP2) from the malaria parasite Plasmodium falciparum provides evidence for active or recent infection, and is utilized for both diagnostic and surveillance purposes, but current laboratory immunoassays for HRP2 are hindered by low sensitivities and high costs. Here we present a new HRP2 immunoassay based on antigen capture through a bead-based system capable of detecting HRP2 at sub-picogram levels. The assay is highly specific and cost-effective, allowing fast processing and screening of large numbers of samples. We utilized the assay to assess results of HRP2-based rapid diagnostic tests (RDTs) in different P. falciparum transmission settings, generating estimates for true performance in the field. Through this method of external validation, HRP2 RDTs were found to perform well in the high-endemic areas of Mozambique and Angola with 86.4% and 73.9% of persons with HRP2 in their blood testing positive by RDTs, respectively, and false-positive rates of 4.3% and 0.5%. However, in the low-endemic setting of Haiti, only 14.5% of persons found to be HRP2 positive by the bead assay were RDT positive. Additionally, 62.5% of Haitians showing a positive RDT test had no detectable HRP2 by the bead assay, likely indicating that these were false positive tests. In addition to RDT validation, HRP2 biomass was assessed for the populations in these different settings, and may provide an additional metric by which to estimate P. falciparum transmission intensity and measure the impact of interventions.
检测来自恶性疟原虫的富含组氨酸蛋白2(HRP2)可为现症感染或近期感染提供证据,并且该检测被用于诊断和监测目的,但目前针对HRP2的实验室免疫测定法受灵敏度低和成本高的阻碍。在此,我们展示了一种基于珠粒系统进行抗原捕获的新型HRP2免疫测定法,该方法能够检测亚皮克级水平的HRP2。该测定法具有高度特异性且成本效益高,能够快速处理和筛查大量样本。我们利用该测定法评估了在不同恶性疟原虫传播环境中基于HRP2的快速诊断检测(RDT)的结果,得出了其在现场的真实性能估计值。通过这种外部验证方法,发现HRP2 RDT在莫桑比克和安哥拉的高流行地区表现良好,血液中含有HRP2的人员通过RDT检测呈阳性的比例分别为86.4%和73.9%,假阳性率分别为4.3%和0.5%。然而,在海地的低流行环境中,通过珠粒测定法检测为HRP2阳性的人员中只有14.5%通过RDT检测呈阳性。此外,62.5% RDT检测呈阳性的海地人通过珠粒测定法未检测到可检测水平的HRP2,这可能表明这些是假阳性检测结果。除了RDT验证外,还评估了这些不同环境中人群的HRP2生物量,这可能提供一个额外的指标,用以估计恶性疟原虫的传播强度并衡量干预措施的影响。